A Novartis castoff with a troubled past headlines Chinese biotech's Hong Kong IPO quest
Taking on a failed drug from one of biopharma’s biggest players and spinning it into a winner is never an easy task. But in the go-go world of Chinese oncology, any risk is a risk worth taking — and one biotech’s gamble could soon pay off.
Adlai Nortye, a Hangzhou, China-based biotech with operations in North Brunswick, NJ, has applied to trade on the Hong Kong Exchange just days after scoring a fundraising round to pursue its license-heavy business model, according to a Tuesday filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.